MMRGlobal CEO Comments on ONC HIT Policy Committee Report in Calling Attention to Company's Patented Lifeline

LOS ANGELES, CA--(Marketwired - Apr 5, 2013) -   MMRGlobal, Inc. (OTCQB: MMRF) ("MMR") today announced that in an ONC Health IT Policy Committee report presented on April 3, 2013, it was discussed that the nationwide data exchange problem for health records could be solved through the use of unique identifiers including telephone numbers. According to Robert H. Lorsch, MMRGlobal CEO, "Based on a 2004 Executive Order calling for an interoperable nationwide system of electronic patient records to give most Americans access to their personal health information within 10 years, we created our MyMedicalRecords Personal Health Record utilizing 10-digit telephone numbers." Starting in 2005, through its wholly owned subsidiary, MyMedicalRecords, Inc., MMR recognized that the one piece of equipment in every healthcare professional's office, accessible by any patient anywhere in the world then and now, is the telephone. The Company invented its MyMedicalRecords PHR platform built on its patented technologies integrating Internet, fax and voice which includes the deployment of 10-digit telephone numbers as a patient's "Lifeline."

MMR is positioned to benefit from the growth of health IT by selling or licensing its products and services to healthcare professionals who need to provide patients online access to their personal health information through a patient portal or PHR starting in 2014. As a result, while the industry struggles to deal with interoperability, the Company, through its MyMedicalRecords PHR, offers interoperability to any doctor, hospital or other healthcare professional in the world today. MMR maintains an extensive database of Lifeline telephone numbers at all times and has long been capable of supporting the market with its patented Lifeline IP. The Company is ready to respond to the needs of healthcare providers and also insurers, pharmacies, employers, unions, health and wellness professionals, and affinity and other membership organizations with the ability to quickly deploy secure, cost-effective Personal Health Record solutions to individuals and their family.

Last month, MMR also announced seamless connectivity between the MyMedicalRecords Personal Health Record and Electronic Medical Record systems in medical clinics starting April 15, 2013. The new features facilitate connectivity with any EMR or EHR system and also laboratory reporting systems. Using an HL7 interface, MMR will be able to populate data, such as a Continuity of Care Document ("CCD"), directly to the patient as well as lab test results, medication lists and other discrete data, which will be directly deposited into the MyMedicalRecords PHR. At the option of the patient, the system will also be able to push PDFs and other personally managed health information from the patient's confidentially maintained files directly into an EMR or EHR. The April 15^th deployment is part of a joint development effort with a 4medica EMR client using 4medica's Certified for Meaningful Use Integrated Electronic Health Record (4medica iEHR®); however, the system will be available to any EMR system

MMR is a leading provider of Personal Health Records, MyEsafeDepositBox storage solutions and electronic document management and imaging systems for healthcare professionals. MMR currently has seven U.S. health IT patents: U.S. Patent Nos. 8,301,466; 8,352,287; 8,352,288; 8,121,855; 8,117,646; 8,117,045; and 8,321,240. The MMR Patent Portfolio includes additional applications and continuation applications with nearly 400 claims. The patents involve inventions pertaining to Personal Health Records, Patient Portals and other Electronic Health Record systems. MMR also has been granted patents and has other pending applications in countries of commercial interest including Australia, Singapore, New Zealand, Mexico, Japan, Canada, Hong Kong, South Korea, Israel, and European nations. A special report published on January 22, 2013 concluded that the range of value for the Company's U.S. health IT patents could reach between $600 million to $1.1 billion in revenue based on what is described as conservative estimates of a market projected to reach a GDP value of $19 billion. (For additional information see http://michaelbass.com/PDF/Patent_Valuation.pdf).

About MMRGlobal
MMRGlobal, Inc., through its wholly-owned operating subsidiary, MyMedicalRecords, Inc., provides secure and easy-to-use online Personal Health Records ("PHRs") and electronic safe deposit box storage solutions, serving consumers, healthcare professionals, employers, insurance companies, financial institutions, retail pharmacies, and professional organizations and affinity groups. The MyMedicalRecords PHR enables individuals and families to access their medical records and other important documents, such as birth certificates, passports, insurance policies and wills, anytime from anywhere using the Internet. MyMedicalRecords is built on proprietary, patented technologies to allow documents, images and voicemail messages to be transmitted and stored in the system using a variety of methods, including fax, phone, or file upload without relying on any specific electronic medical record platform to populate a user's account. The Company's professional offering, MMRPro, is designed to give physicians' offices an easy and cost-effective solution to digitizing paper-based medical records and sharing them with patients through an integrated patient portal. Through its merger with Favrille, Inc. in January 2009, the Company acquired intellectual property biotech assets that include anti-CD20 antibodies and data and samples from its FavId™/Specifid™ vaccine clinical trials for the treatment of B-Cell Non-Hodgkin's lymphoma. To learn more about MMRGlobal, Inc. visit www.mmrglobal.com. View demos and video tutorials of the Company's products and services at www.mmrtheater.com.

Forward-Looking Statements
All statements in this press release that are not strictly historical in nature, including, without limitation, intellectual property enforcement actions, infringement claims or litigation, intellectual property licenses, and future performance, management's expectations, beliefs, intentions, estimates or projections, constitute "forward-looking statements." Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. Some can be identified by the use of words (and their derivations) such as "need," "possibility," "potential," "intend," "offer," "development," "if," "negotiate," "when," "begun," "believe," "achieve," "will," "estimate," "expect," "maintain," "plan," and "continue," or the negative of these words. Actual outcomes and results of operations and the timing of selected events may differ materially from the results predicted, and any reported results should not be considered as an indication of future performance. Such statements are necessarily based on assumptions and estimates and are subject to various risks and uncertainties, including those relating to the possible invalidity of the underlying assumptions and estimates and possible changes or developments in economic, business, industry, market, legal and regulatory circumstances and conditions and actions taken or omitted to be taken by third parties, including customers, suppliers, business partners, potential licensees, competitors and legislative, judicial and other governmental authorities and officials. Factors that could cause or contribute to such differences include, but are not limited to: unexpected outcomes with respect to intellectual property enforcement actions, claims of intellectual property infringement and general intellectual property litigation; our ability to maintain, develop, monetize and protect our patent portfolio for both the Company's health IT and biotechnology intellectual property assets in the U.S. and internationally; the timing of milestone payments in connection with licensing our intellectual property; our ability to establish and maintain strategic relationships; changes in our relationships with our licensees; the risk the Company's products are not adopted or viewed favorably by the healthcare community and consumer retail market; business prospects, results of operations or financial condition; risks related to the current uncertainty and instability in financial and lending markets, including global economic uncertainties; the timing and volume of sales and installations; the length of sales cycles and the installation process; the market's acceptance of new product and service introductions; competitive product offerings and promotions; changes in government laws and regulations including the 2009 HITECH Act and changes in Meaningful Use and the 2010 Affordable Care Act; future changes in tax legislation and initiatives in the healthcare industry; undetected errors in our products; the possibility of interruption at our data centers; risks related to third party vendors; risks related to obtaining and integrating third-party licensed technology; risks related to a security breach by third parties; risks associated with recruitment and retention of key personnel; other litigation matters; uncertainties associated with doing business internationally across borders and territories; and additional risks discussed in the Company's filings with the Securities and Exchange Commission, including disclosures about the Company's relationship with the Michael Bass Group since 2009. The Company is providing this information as of the date of this release and, except as required by applicable law, does not undertake any obligation to update any forward-looking statements contained in this release as a result of new information, future events or otherwise.